ImageneBio, Inc.
IMA Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 27, 2026
$4.02
KIRA · Stoqly’s AI analyst, in plain words
- ImageneBio, Inc. had $0.8M of revenue in fiscal 2025, down 77.1% on the year before. Over five years, revenue changed −38.6% a year on average.
- Its operating margin was −6,056.4%, down 4,999.2 pts: of every 100 in sales, about −6,056 is left after running the business.
- ImageneBio, Inc. lost $45.3M in fiscal 2025.
- ImageneBio, Inc. has $135M more cash than debt.
Market cap
$65.0M
P/E
—
Revenue
$0.8M
Net income
−$45.3M
Free cash flow
—
Operating margin
−6,056.4%
ImageneBio, Inc. in 30 seconds · fiscal 2025
Are sales growing?
−77.1%
No. Sales fell 77.1% last year.
Does it make a profit?
−5,668.6%
No. It lost money last year.
How healthy are the accounts?
3 / 7
Weak. It passes 3 of 7 health tests.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What ImageneBio, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 10, 2026
- Legal name
- ImageneBio, Inc.
- CIK
- 0001835579
ImageneBio, Inc. · IMA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $31.0M | $15.6M | $9.2M | $3.5M | $0.8M |
| Revenue growth | 237.0% | −49.6% | −41.3% | −61.8% | −77.1% |
| Operating margin | −110.2% | −454.0% | −823.3% | −1,057.1% | −6,056.4% |
| Net income | −$34.1M | −$68.8M | −$68.2M | −$36.6M | −$45.3M |
| Net margin | −110.1% | −440.3% | −744.2% | −1,044.8% | −5,668.6% |
| Diluted EPS | −$1.22 | −$1.90 | −$1.63 | −$22.10 | −$9.64 |
| Cash | |||||
| Cash from operations | −$60.3M | −$74.1M | −$79.7M | −$21.3M | −$47.8M |
| Capital expenditure | $1.8M | $1.4M | $0.4M | — | — |
| Free cash flow | −$62.0M | −$75.5M | −$80.2M | — | — |
| FCF margin | −200.1% | −483.7% | −875.1% | — | — |
| Share buybacks | — | — | $0.7M | — | — |
| Share count change | 911.9% | 29.3% | 15.3% | 15.6% | — |
| Debt and strength | |||||
| Cash and short-term investments | $232M | $157M | $175M | $12.1M | $135M |
| Debt incl. finance leases | — | — | — | $7.5M | $0.0M |
| Shareholders' equity | $208M | $147M | −$126M | −$161M | $133M |
| Current ratio | 8.7x | 7.4x | 12.6x | 0.7x | 12.5x |
| Returns and quality | |||||
| Return on equity | −63.9% | −38.8% | −653.5% | — | — |
| Return on tangible equity | −16.4% | −46.8% | — | — | −39.4% |
| Piotroski F-score | 3 | 0 | 2 | 2 | 3 |
| Altman Z'' | 8.2 | 4.6 | −7.7 | −64.1 | 5.6 |
Insiders bought, 12 months
$0.1M
1 insider
Insiders sold, 12 months
$0.0M
1 insider
Of sales under plans
0%
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
ImageneBio, Inc. · IMA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $4.02 a share, the company is worth $65.0M.
Source: SEC EDGAR XBRL filings (CIK 0001835579). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.